Investors
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors.
Company Profile
We are a pioneering novel T-cell reprograming technologies designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. We apply our proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved and durable clinical outcomes.
